Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial

Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the abi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular genetics and metabolism 2019-05, Vol.127 (1), p.86-94
Hauptverfasser: Ramaswami, Uma, Bichet, Daniel G., Clarke, Lorne A., Dostalova, Gabriela, Fainboim, Alejandro, Fellgiebel, Andreas, Forcelini, Cassiano M., An Haack, Kristina, Hopkin, Robert J., Mauer, Michael, Najafian, Behzad, Scott, C. Ronald, Shankar, Suma P., Thurberg, Beth L., Tøndel, Camilla, Tylki-Szymanska, Anna, Bénichou, Bernard, Wijburg, Frits A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 94
container_issue 1
container_start_page 86
container_title Molecular genetics and metabolism
container_volume 127
creator Ramaswami, Uma
Bichet, Daniel G.
Clarke, Lorne A.
Dostalova, Gabriela
Fainboim, Alejandro
Fellgiebel, Andreas
Forcelini, Cassiano M.
An Haack, Kristina
Hopkin, Robert J.
Mauer, Michael
Najafian, Behzad
Scott, C. Ronald
Shankar, Suma P.
Thurberg, Beth L.
Tøndel, Camilla
Tylki-Szymanska, Anna
Bénichou, Bernard
Wijburg, Frits A.
description Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-weekly (n = 15) for 5 years. All had plasma/urine GL-3 accumulation but no clinically evident organ involvement. The primary outcome was GL-3 accumulation in superficial skin capillary endothelium (SSCE). The mean age was 11.6 (range: 5–18) years and all but one of the 31 patients had classic GLA mutations. In the overall cohort, shifts from non-0 to 0-scores for SSCE GL-3 were significant at years 1, 3, and 5, but results were variable. Plasma GL-3 normalized and urine GL-3 reduced substantially. Higher anti-agalsidase beta antibody titers were associated with less robust SSCE GL-3 clearance and higher urine GL-3 levels. Renal function remained stable and normal. Most Fabry signs and symptoms tended to stabilize; abdominal pain was significantly reduced (−26.3%; P = .0215). No new clinical major organ complications were observed. GL-3 accumulation and cellular and vascular injury were present in baseline kidney biopsies (n = 7). Treatment effects on podocyte GL-3 content and foot process width were highly variable. Fabry arteriopathy overall increased in severity. Two patients withdrew and 2 had their agalsidase beta dose increased. Our findings increase the limited amount of available data on long-term effects of enzyme replacement therapy in pediatric, classic Fabry patients. The low-dose regimens studied here over a period of 5 years did not demonstrate a consistent benefit among the patients in terms of controlling symptomatology, urine GL-3 levels, and pathological histology. The current available evidence supports treatment of pediatric, classic male Fabry patients at the approved agalsidase beta dose of 1.0 mg/kg 2-weekly if these patients are considered for enzyme replacement therapy with agalsidase beta. •Male pediatric, mostly classic Fabry patients, received 1 of 2 low-dose agalsidase be
doi_str_mv 10.1016/j.ymgme.2019.03.010
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2210242285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1096719218307662</els_id><sourcerecordid>2210242285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-867efc5a1aec18f3a22ca29c2e5b059122e19f8d3819bc12cea182f76874ac393</originalsourceid><addsrcrecordid>eNp9kM1OHDEQhC0UBITkCSJFPnKZidvzayQOaAVJpJW4JGerx-4hXs2MN7YXtHl6DAscc-qSuqpL_TH2BUQJAtpvm3I_389USgGqFFUpQByxMxCqLTop2g9vGpQ8ZR9j3AgB0Kj6hJ1WQvWdgu6MPaz9Y2F9JI73OEVnMcuBEvIUCNNMS-Ju4TNOxLdkHabgDN9icnkT-aNLf_gtDmHPrYuUw5f8mjfFnjDwgIv1s_tHlhu_pOCnKct8AKdP7HjMdfT5dZ6z37c3v1Y_ivXd95-r63VhalGnom87Gk2DgGSgHyuU0qBURlIziEaBlARq7G3VgxoMSEMIvRy7tu9qNJWqztnF4e42-L87iknPLhqaJlzI76KWEoSspeybbK0OVhN8jIFGvQ1uxrDXIPQzcL3RL8D1M3AtKp2B59TX14LdMJN9z7wRzoarg4Hymw-Ogo4mszOZZSCTtPXuvwVPai-T_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2210242285</pqid></control><display><type>article</type><title>Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial</title><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Ramaswami, Uma ; Bichet, Daniel G. ; Clarke, Lorne A. ; Dostalova, Gabriela ; Fainboim, Alejandro ; Fellgiebel, Andreas ; Forcelini, Cassiano M. ; An Haack, Kristina ; Hopkin, Robert J. ; Mauer, Michael ; Najafian, Behzad ; Scott, C. Ronald ; Shankar, Suma P. ; Thurberg, Beth L. ; Tøndel, Camilla ; Tylki-Szymanska, Anna ; Bénichou, Bernard ; Wijburg, Frits A.</creator><creatorcontrib>Ramaswami, Uma ; Bichet, Daniel G. ; Clarke, Lorne A. ; Dostalova, Gabriela ; Fainboim, Alejandro ; Fellgiebel, Andreas ; Forcelini, Cassiano M. ; An Haack, Kristina ; Hopkin, Robert J. ; Mauer, Michael ; Najafian, Behzad ; Scott, C. Ronald ; Shankar, Suma P. ; Thurberg, Beth L. ; Tøndel, Camilla ; Tylki-Szymanska, Anna ; Bénichou, Bernard ; Wijburg, Frits A.</creatorcontrib><description>Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-weekly (n = 15) for 5 years. All had plasma/urine GL-3 accumulation but no clinically evident organ involvement. The primary outcome was GL-3 accumulation in superficial skin capillary endothelium (SSCE). The mean age was 11.6 (range: 5–18) years and all but one of the 31 patients had classic GLA mutations. In the overall cohort, shifts from non-0 to 0-scores for SSCE GL-3 were significant at years 1, 3, and 5, but results were variable. Plasma GL-3 normalized and urine GL-3 reduced substantially. Higher anti-agalsidase beta antibody titers were associated with less robust SSCE GL-3 clearance and higher urine GL-3 levels. Renal function remained stable and normal. Most Fabry signs and symptoms tended to stabilize; abdominal pain was significantly reduced (−26.3%; P = .0215). No new clinical major organ complications were observed. GL-3 accumulation and cellular and vascular injury were present in baseline kidney biopsies (n = 7). Treatment effects on podocyte GL-3 content and foot process width were highly variable. Fabry arteriopathy overall increased in severity. Two patients withdrew and 2 had their agalsidase beta dose increased. Our findings increase the limited amount of available data on long-term effects of enzyme replacement therapy in pediatric, classic Fabry patients. The low-dose regimens studied here over a period of 5 years did not demonstrate a consistent benefit among the patients in terms of controlling symptomatology, urine GL-3 levels, and pathological histology. The current available evidence supports treatment of pediatric, classic male Fabry patients at the approved agalsidase beta dose of 1.0 mg/kg 2-weekly if these patients are considered for enzyme replacement therapy with agalsidase beta. •Male pediatric, mostly classic Fabry patients, received 1 of 2 low-dose agalsidase beta regimens for 5 years.•Patients with higher anti-agalsidase beta antibody titers had less robust skin GL-3 clearance (primary endpoint).•Fabry symptoms tended to stabilize, but vascular alterations were not influenced and podocyte GL-3 clearance was variable.•If pediatric classic patients are considered for agalsidase beta therapy, the approved dose (1 mg/kg 2-weekly) is advised.</description><identifier>ISSN: 1096-7192</identifier><identifier>EISSN: 1096-7206</identifier><identifier>DOI: 10.1016/j.ymgme.2019.03.010</identifier><identifier>PMID: 30987917</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Agalsidase beta ; Biopsy ; Classic phenotype ; Clinical outcomes ; Enzyme replacement therapy ; Fabry disease ; Globotriaosylceramide ; Pediatric ; Podocytes ; Superficial skin capillary endothelium ; Symptoms</subject><ispartof>Molecular genetics and metabolism, 2019-05, Vol.127 (1), p.86-94</ispartof><rights>2019 The Authors</rights><rights>Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-867efc5a1aec18f3a22ca29c2e5b059122e19f8d3819bc12cea182f76874ac393</citedby><cites>FETCH-LOGICAL-c404t-867efc5a1aec18f3a22ca29c2e5b059122e19f8d3819bc12cea182f76874ac393</cites><orcidid>0000-0002-9331-0926 ; 0000-0003-4809-1274</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ymgme.2019.03.010$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30987917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramaswami, Uma</creatorcontrib><creatorcontrib>Bichet, Daniel G.</creatorcontrib><creatorcontrib>Clarke, Lorne A.</creatorcontrib><creatorcontrib>Dostalova, Gabriela</creatorcontrib><creatorcontrib>Fainboim, Alejandro</creatorcontrib><creatorcontrib>Fellgiebel, Andreas</creatorcontrib><creatorcontrib>Forcelini, Cassiano M.</creatorcontrib><creatorcontrib>An Haack, Kristina</creatorcontrib><creatorcontrib>Hopkin, Robert J.</creatorcontrib><creatorcontrib>Mauer, Michael</creatorcontrib><creatorcontrib>Najafian, Behzad</creatorcontrib><creatorcontrib>Scott, C. Ronald</creatorcontrib><creatorcontrib>Shankar, Suma P.</creatorcontrib><creatorcontrib>Thurberg, Beth L.</creatorcontrib><creatorcontrib>Tøndel, Camilla</creatorcontrib><creatorcontrib>Tylki-Szymanska, Anna</creatorcontrib><creatorcontrib>Bénichou, Bernard</creatorcontrib><creatorcontrib>Wijburg, Frits A.</creatorcontrib><title>Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial</title><title>Molecular genetics and metabolism</title><addtitle>Mol Genet Metab</addtitle><description>Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-weekly (n = 15) for 5 years. All had plasma/urine GL-3 accumulation but no clinically evident organ involvement. The primary outcome was GL-3 accumulation in superficial skin capillary endothelium (SSCE). The mean age was 11.6 (range: 5–18) years and all but one of the 31 patients had classic GLA mutations. In the overall cohort, shifts from non-0 to 0-scores for SSCE GL-3 were significant at years 1, 3, and 5, but results were variable. Plasma GL-3 normalized and urine GL-3 reduced substantially. Higher anti-agalsidase beta antibody titers were associated with less robust SSCE GL-3 clearance and higher urine GL-3 levels. Renal function remained stable and normal. Most Fabry signs and symptoms tended to stabilize; abdominal pain was significantly reduced (−26.3%; P = .0215). No new clinical major organ complications were observed. GL-3 accumulation and cellular and vascular injury were present in baseline kidney biopsies (n = 7). Treatment effects on podocyte GL-3 content and foot process width were highly variable. Fabry arteriopathy overall increased in severity. Two patients withdrew and 2 had their agalsidase beta dose increased. Our findings increase the limited amount of available data on long-term effects of enzyme replacement therapy in pediatric, classic Fabry patients. The low-dose regimens studied here over a period of 5 years did not demonstrate a consistent benefit among the patients in terms of controlling symptomatology, urine GL-3 levels, and pathological histology. The current available evidence supports treatment of pediatric, classic male Fabry patients at the approved agalsidase beta dose of 1.0 mg/kg 2-weekly if these patients are considered for enzyme replacement therapy with agalsidase beta. •Male pediatric, mostly classic Fabry patients, received 1 of 2 low-dose agalsidase beta regimens for 5 years.•Patients with higher anti-agalsidase beta antibody titers had less robust skin GL-3 clearance (primary endpoint).•Fabry symptoms tended to stabilize, but vascular alterations were not influenced and podocyte GL-3 clearance was variable.•If pediatric classic patients are considered for agalsidase beta therapy, the approved dose (1 mg/kg 2-weekly) is advised.</description><subject>Agalsidase beta</subject><subject>Biopsy</subject><subject>Classic phenotype</subject><subject>Clinical outcomes</subject><subject>Enzyme replacement therapy</subject><subject>Fabry disease</subject><subject>Globotriaosylceramide</subject><subject>Pediatric</subject><subject>Podocytes</subject><subject>Superficial skin capillary endothelium</subject><subject>Symptoms</subject><issn>1096-7192</issn><issn>1096-7206</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OHDEQhC0UBITkCSJFPnKZidvzayQOaAVJpJW4JGerx-4hXs2MN7YXtHl6DAscc-qSuqpL_TH2BUQJAtpvm3I_389USgGqFFUpQByxMxCqLTop2g9vGpQ8ZR9j3AgB0Kj6hJ1WQvWdgu6MPaz9Y2F9JI73OEVnMcuBEvIUCNNMS-Ju4TNOxLdkHabgDN9icnkT-aNLf_gtDmHPrYuUw5f8mjfFnjDwgIv1s_tHlhu_pOCnKct8AKdP7HjMdfT5dZ6z37c3v1Y_ivXd95-r63VhalGnom87Gk2DgGSgHyuU0qBURlIziEaBlARq7G3VgxoMSEMIvRy7tu9qNJWqztnF4e42-L87iknPLhqaJlzI76KWEoSspeybbK0OVhN8jIFGvQ1uxrDXIPQzcL3RL8D1M3AtKp2B59TX14LdMJN9z7wRzoarg4Hymw-Ogo4mszOZZSCTtPXuvwVPai-T_Q</recordid><startdate>201905</startdate><enddate>201905</enddate><creator>Ramaswami, Uma</creator><creator>Bichet, Daniel G.</creator><creator>Clarke, Lorne A.</creator><creator>Dostalova, Gabriela</creator><creator>Fainboim, Alejandro</creator><creator>Fellgiebel, Andreas</creator><creator>Forcelini, Cassiano M.</creator><creator>An Haack, Kristina</creator><creator>Hopkin, Robert J.</creator><creator>Mauer, Michael</creator><creator>Najafian, Behzad</creator><creator>Scott, C. Ronald</creator><creator>Shankar, Suma P.</creator><creator>Thurberg, Beth L.</creator><creator>Tøndel, Camilla</creator><creator>Tylki-Szymanska, Anna</creator><creator>Bénichou, Bernard</creator><creator>Wijburg, Frits A.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9331-0926</orcidid><orcidid>https://orcid.org/0000-0003-4809-1274</orcidid></search><sort><creationdate>201905</creationdate><title>Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial</title><author>Ramaswami, Uma ; Bichet, Daniel G. ; Clarke, Lorne A. ; Dostalova, Gabriela ; Fainboim, Alejandro ; Fellgiebel, Andreas ; Forcelini, Cassiano M. ; An Haack, Kristina ; Hopkin, Robert J. ; Mauer, Michael ; Najafian, Behzad ; Scott, C. Ronald ; Shankar, Suma P. ; Thurberg, Beth L. ; Tøndel, Camilla ; Tylki-Szymanska, Anna ; Bénichou, Bernard ; Wijburg, Frits A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-867efc5a1aec18f3a22ca29c2e5b059122e19f8d3819bc12cea182f76874ac393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Agalsidase beta</topic><topic>Biopsy</topic><topic>Classic phenotype</topic><topic>Clinical outcomes</topic><topic>Enzyme replacement therapy</topic><topic>Fabry disease</topic><topic>Globotriaosylceramide</topic><topic>Pediatric</topic><topic>Podocytes</topic><topic>Superficial skin capillary endothelium</topic><topic>Symptoms</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramaswami, Uma</creatorcontrib><creatorcontrib>Bichet, Daniel G.</creatorcontrib><creatorcontrib>Clarke, Lorne A.</creatorcontrib><creatorcontrib>Dostalova, Gabriela</creatorcontrib><creatorcontrib>Fainboim, Alejandro</creatorcontrib><creatorcontrib>Fellgiebel, Andreas</creatorcontrib><creatorcontrib>Forcelini, Cassiano M.</creatorcontrib><creatorcontrib>An Haack, Kristina</creatorcontrib><creatorcontrib>Hopkin, Robert J.</creatorcontrib><creatorcontrib>Mauer, Michael</creatorcontrib><creatorcontrib>Najafian, Behzad</creatorcontrib><creatorcontrib>Scott, C. Ronald</creatorcontrib><creatorcontrib>Shankar, Suma P.</creatorcontrib><creatorcontrib>Thurberg, Beth L.</creatorcontrib><creatorcontrib>Tøndel, Camilla</creatorcontrib><creatorcontrib>Tylki-Szymanska, Anna</creatorcontrib><creatorcontrib>Bénichou, Bernard</creatorcontrib><creatorcontrib>Wijburg, Frits A.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular genetics and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramaswami, Uma</au><au>Bichet, Daniel G.</au><au>Clarke, Lorne A.</au><au>Dostalova, Gabriela</au><au>Fainboim, Alejandro</au><au>Fellgiebel, Andreas</au><au>Forcelini, Cassiano M.</au><au>An Haack, Kristina</au><au>Hopkin, Robert J.</au><au>Mauer, Michael</au><au>Najafian, Behzad</au><au>Scott, C. Ronald</au><au>Shankar, Suma P.</au><au>Thurberg, Beth L.</au><au>Tøndel, Camilla</au><au>Tylki-Szymanska, Anna</au><au>Bénichou, Bernard</au><au>Wijburg, Frits A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial</atitle><jtitle>Molecular genetics and metabolism</jtitle><addtitle>Mol Genet Metab</addtitle><date>2019-05</date><risdate>2019</risdate><volume>127</volume><issue>1</issue><spage>86</spage><epage>94</epage><pages>86-94</pages><issn>1096-7192</issn><eissn>1096-7206</eissn><abstract>Fabry disease is a rare, X-linked, lifelong progressive lysosomal storage disorder. Severely deficient α-galactosidase A activity in males is associated with the classic phenotype with early-onset, multisystem manifestations evolving to vital organ complications during adulthood. We assessed the ability of 2 low-dose agalsidase beta regimens to lower skin, plasma, and urine globotriaosylceramide (GL-3) levels, and influence clinical manifestations in male pediatric Fabry patients. In this multicenter, open-label, parallel-group, phase 3b study, male patients aged 5–18 years were randomized to receive agalsidase beta at 0.5 mg/kg 2-weekly (n = 16) or 1.0 mg/kg 4-weekly (n = 15) for 5 years. All had plasma/urine GL-3 accumulation but no clinically evident organ involvement. The primary outcome was GL-3 accumulation in superficial skin capillary endothelium (SSCE). The mean age was 11.6 (range: 5–18) years and all but one of the 31 patients had classic GLA mutations. In the overall cohort, shifts from non-0 to 0-scores for SSCE GL-3 were significant at years 1, 3, and 5, but results were variable. Plasma GL-3 normalized and urine GL-3 reduced substantially. Higher anti-agalsidase beta antibody titers were associated with less robust SSCE GL-3 clearance and higher urine GL-3 levels. Renal function remained stable and normal. Most Fabry signs and symptoms tended to stabilize; abdominal pain was significantly reduced (−26.3%; P = .0215). No new clinical major organ complications were observed. GL-3 accumulation and cellular and vascular injury were present in baseline kidney biopsies (n = 7). Treatment effects on podocyte GL-3 content and foot process width were highly variable. Fabry arteriopathy overall increased in severity. Two patients withdrew and 2 had their agalsidase beta dose increased. Our findings increase the limited amount of available data on long-term effects of enzyme replacement therapy in pediatric, classic Fabry patients. The low-dose regimens studied here over a period of 5 years did not demonstrate a consistent benefit among the patients in terms of controlling symptomatology, urine GL-3 levels, and pathological histology. The current available evidence supports treatment of pediatric, classic male Fabry patients at the approved agalsidase beta dose of 1.0 mg/kg 2-weekly if these patients are considered for enzyme replacement therapy with agalsidase beta. •Male pediatric, mostly classic Fabry patients, received 1 of 2 low-dose agalsidase beta regimens for 5 years.•Patients with higher anti-agalsidase beta antibody titers had less robust skin GL-3 clearance (primary endpoint).•Fabry symptoms tended to stabilize, but vascular alterations were not influenced and podocyte GL-3 clearance was variable.•If pediatric classic patients are considered for agalsidase beta therapy, the approved dose (1 mg/kg 2-weekly) is advised.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>30987917</pmid><doi>10.1016/j.ymgme.2019.03.010</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-9331-0926</orcidid><orcidid>https://orcid.org/0000-0003-4809-1274</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1096-7192
ispartof Molecular genetics and metabolism, 2019-05, Vol.127 (1), p.86-94
issn 1096-7192
1096-7206
language eng
recordid cdi_proquest_miscellaneous_2210242285
source ScienceDirect Freedom Collection (Elsevier)
subjects Agalsidase beta
Biopsy
Classic phenotype
Clinical outcomes
Enzyme replacement therapy
Fabry disease
Globotriaosylceramide
Pediatric
Podocytes
Superficial skin capillary endothelium
Symptoms
title Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A05%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low-dose%20agalsidase%20beta%20treatment%20in%20male%20pediatric%20patients%20with%20Fabry%20disease:%20A%205-year%20randomized%20controlled%20trial&rft.jtitle=Molecular%20genetics%20and%20metabolism&rft.au=Ramaswami,%20Uma&rft.date=2019-05&rft.volume=127&rft.issue=1&rft.spage=86&rft.epage=94&rft.pages=86-94&rft.issn=1096-7192&rft.eissn=1096-7206&rft_id=info:doi/10.1016/j.ymgme.2019.03.010&rft_dat=%3Cproquest_cross%3E2210242285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2210242285&rft_id=info:pmid/30987917&rft_els_id=S1096719218307662&rfr_iscdi=true